Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: A mortality assessment study

Addiction

Volumn 104, Issue 6, 2009, Pages 993-999

  Anchersen, Katinka ^a   Clausen, Thomas ^b   Gossop, Michael ^b   Hansteen, Viggo ^b   Waal, Helge ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NONE

Author keywords

Buprenorphine; Dose response; Methadone; Mortality; Prevalence; QTc prolongation

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; DEATH; DEATH CERTIFICATE; DOSE RESPONSE; DRUG OVERDOSE; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; OPIATE ADDICTION; PREVALENCE; QT PROLONGATION; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUPRENORPHINE; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NORWAY; OPIOID-RELATED DISORDERS; PREVALENCE; YOUNG ADULT;

EID: 65549145066     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02549.x     Document Type: Article

References (38)

1. Vincent G. M. Long QT syndrome. Cardiol Clin 2000 18 : 309 25.
2. Cavero I., Mestre M., Guillon J. M., Crumb W. Drugs that prolong the QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother 2000 1 : 947 73.
3. Faber T., Zehender M., Just H. Drug-induced torsades de pointes. Drug Safety 1994 11 : 463 76.
4. Zermrak W. R., Kenna G. A. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008 65 : 1029 38.
5. Sicouri S., Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Exp Opin Drug Saf 2008 7 : 181 94.
6. Gennari J. F. Hypokalemia (review). N Engl J Med 1998 339 : 451 8.
7. January C. T., Gong Q., Zhou Z. Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 2000 11 : 1413 18. (Pubitemid 32016868)
8. Deamer R. L., Wilson D. R., Clark D. S., Prichard J. G. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001 20 : 7 14. (Pubitemid 33095745)
9. Clark N., Lintzeris N., Gjibers A., Whelan G., Dunlop A., Ritter A. et al. LAAM mainenance vs. methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2002 2 : CD002210.
10. US Food and Drug Administration. Drug Shortage: Drug to be discontinued. Letter from Roxanne 2003. Available at: http://www.fda.gov/cder/drug/shortages/ orlaam.htm
11. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (review). Cochrane Database Syst Rev 2008 3 : CD002207.
12. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007 11 : 1 171. (Pubitemid 47207726)
13. Marsch L. A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, risk behavior and criminality: a meta-analysis. Addiction 1998 93 : 515 32. (Pubitemid 28188071)
14. Krantz M. J., Lewkowiez L., Hays H., Woodroffe M. A., Robertson A. D., Mehler P. S. Torsades de pointes associated with very-high-dose methadone. Ann Intern Med 2002 17 : 501 4.
15. Martell B. A., Arnsten J. H., Ray B., Gourevitch M. N. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003 139 : 154 5. (Pubitemid 38129111)
16. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., Guma J. R. et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003 92 : 995 7. (Pubitemid 37214820)
17. Cruciani R. A., Sekine R., Homel P., Lussier D., Yap Y., Suzuki Y et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005 29 : 385 91. (Pubitemid 40602519)
18. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005 11 : 44 9. (Pubitemid 40082210)
19. Peles E., Bodner G., Kreek M. J., Rados V., Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients - a cross-sectional study. Addiction 2007 102 : 289 300. (Pubitemid 46096291)
20. Ehret G. B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B. et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006 166 : 1280 7. (Pubitemid 43967579)
21. Wedam E. F., Bigelow G. E., Johnson R. E., Nuzzo P. A., Haigney M. C. P. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007 167 : 2469 75. (Pubitemid 350254906)
22. Krantz M. J., Kutinsky I. B., Robertson A. D., Mehler P. S. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy 2003 23 : 802 5. (Pubitemid 36629083)
23. Katchman A. N., McGroary K. A., Kilborn M. J., Kornick C. A., Manfredi P. L., Woosley R. L. et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002 303 : 688 94. (Pubitemid 35231242)
24. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001 45 : 285. (Pubitemid 32042714)
25. Krantz M. J., Garcia J. A., Mehler P. S. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsades de pointes. Pharmacotherapy 2005 25 : 611 4. (Pubitemid 40471501)
26. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008 94 : 151 7.
27. Hansen M. B., Kornør H., Waal H. Statusrapport 2003 (OMT in Norway. Evaluation report 2003). Report no: 1/2003. Oslo : Norwegian Centre for Addiction Research 2003.
28. Bazett H. C. An analysis of the time-relation of electrocardiograms. Heart 1920 7 : 353 70.
29. Montanez A., Ruskin J. N., Herbert P. R., Lamas G. A., Hennekens C. H. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004 164 : 943 8. (Pubitemid 38581512)
30. Waal H., Clausen T., Håseth A., Lillevold P. LAR i Norge. Statusrapport 2007 (OMT in Norway. Evaluation report 2007). Report no: SERAF 1/2008. Oslo : Norwegian Centre for Addiction Research 2008.
31. Krantz M. J. Heterogeneous impact of methadone on the QTc interval: what are the clinical implications? J Addict Dis 2008 27 : 5 9.
32. Makkar R. R., Fromm B. S., Steinman R. T., Meissner M. D., Lehmann M. H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993 270 : 2590 7. (Pubitemid 23346699)
33. Benoit S. R., Mendelsohn A. B., Nourjah P., Staffa J. A., Graham D. J. Risk factors for prolonged QTc among US adults: third national health and nutrition examination survey. Eur J Cardiovasc Prev Rehabil 2005 12 : 363 8. (Pubitemid 41192168)
34. Benchimol A., Bartall H., Desser K. Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 1978 88 : 519 20. (Pubitemid 8330305)
35. Magnano A. R., Talathoti N. B., Hallur R., Jurus D. T., Dizon J., Holleran S. et al. Effect of acute cocaine administration on the QTc interval of habitual users. Am J Cardiol 2006 97 : 1244 6.
36. Haigney M. C., Alam S., Tebo S., Marhefka G., Elkashef A., Kahn R et al. Intravenous cocaine and QT variability. J Cardiovasc Electrophysiol 2006 17 : 610 6.
37. Haning W., Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction 2007 102 : 70 5. (Pubitemid 46328214)
38. Schmittner J., Krantz M. J. QTc prolongation in methadone maintenance: fact and fiction. Heroin Addict Relat Clin Probl 2006 6 : 41 52. (Pubitemid 46129269)